Is Alphabet's New CEO, Sundar Pichai, Ready for What's to Come?
Taking over for Google's founders, Pichai will be the one to navigate the company through an overdue rethinking of its business, for better or worse.
Why Investors Should Avoid Zscaler
The cybersecurity company reported strong fiscal first-quarter results and raised its guidance, but its stock price corresponds to higher expectations.
This Dividend-Paying Chip Stock Could Switch Up a Gear in 2020
Secular end-market growth should be a catalyst for chipmaker Analog Devices in the new year.
At least this pair of winners is getting cheerful in advance of the holidays.
More than six years after the last Mac Pro was launched, the powerful computer is back in a new form.
A strong quarterly report and analyst upgrade left the payroll and HR technology leader soaring.
The programmatic ad leader rallied after a positive quarterly report and the successful launch of Disney+.
The company is joining with a rival "to create the premier, Texas-based super regional bank."
Investors cheered the cannabis company's choice for its new chief executive.
Two big deals for cancer drug companies made news today. Merck plans to buy ArQule and Sanofi will pay up to buy Synthorx.
Recent shipments data from IDC shows that the iPhone maker's strategy is spot on.
Find out why one of these stocks lost more than half its value.
Find out why these stocks stood out on a quiet day on Wall Street.
Shares of the apparel retailer gained again on last week's earnings report.
XBiotech announced a massive deal with Johnson & Johnson subsidiary Janssen, which is thrusting the overlooked biopharma onto the radars of investors.
Investors should remember that CRISPR isn't the only gene editing technology out there. Case in point: ARCUS.
Data presentations at a major scientific conference and the acquisition of another small biotech sparked investors' enthusiasm.
Recessions and sell-offs are part and parcel of a free economy, but some companies are more exposed to the consequences of a downturn than others.
The RV giant is building a healthier margin profile as it waits for domestic demand to rebound.
Though it may not garner the same publicity as software or streaming services, hardware is an integral part of these companies competing with one another.
Precision BioSciences provided an expanded update from its first clinical asset. Investors weren't impressed.
Tariffs are coming for Apple, and Intel is working on scaling quantum computers.
Activist investors and a new quarterly filing breathed life into 2U's battered stock.